Skip to content

Olema Pharmaceuticals

US · OLMA #3521 by market cap Listed 2020
7.02 -0.13 -1.82%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 7.01 -1.96%
After-hours 7.02 0.00%
Overnight 6.97 -2.52%
13.556.417.022026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on OLMA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -51.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 19.6% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -36.6% Better than 11%
Return on invested capital -40.0% Better than 8%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -34.3% Better than 14%
6-month return -48.7% Better than 8%
12-month return (ex latest month) -69.7% Better than 0%
Distance below 52-week high 80.6% Better than 2%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 10.0x Better than 93%
Debt to assets 0.8% Better than 94%
Interest coverage -32.9x Better than 8%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 360.5% Better than 99%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.14%
1M -3.17%
3M -35.60%
6M -49.71%
YTD -71.92%
1Y -68.11%
3Y -55.99%
5Y -69.16%

Key statistics

Price & volume

Prev close
7.15
Open
7.01
Day range
6.88 - 7.36
Avg price
7.08
Volume
1.26M
Turnover
8.89M
Amplitude
6.64%
52-week range
6.24 - 36.26

Valuation

P/E
-3.75
P/E (TTM)
-2.93
P/B
1.67
EPS
-1.87
Net profit
-163.82M
Net assets
368.82M

Share structure

Market cap
615.00M
Float cap
416.28M
Shares out
87.61M
Float shares
59.30M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-11-19
52-week range 3% of range
6.24 36.26

80.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-6.03M net over the window

Short interest

Shares short
17.12M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Olema Pharmaceuticals (OLMA)?

Olema Pharmaceuticals last traded at 7.02. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Olema Pharmaceuticals's market cap?

About 615.00M.

What is the P/E ratio of Olema Pharmaceuticals?

The trailing twelve-month P/E is -2.93. The Valuation tab shows it against the stock's own five-year range.

Does Olema Pharmaceuticals pay a dividend?

Olema Pharmaceuticals does not currently pay a regular dividend.

Is Olema Pharmaceuticals a buy according to analysts?

The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 32.33, which implies 360.5% upside from the current price. This is not investment advice.

What is Olema Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Olema Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Olema Pharmaceuticals discussion 0 comments

Add a comment